Immediate Impact
57 standout
Citing Papers
The present and future of bispecific antibodies for cancer therapy
2024 Standout
An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023)
2024 Standout
Works of Luning Zhuang being referenced
FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
2019
Osimertinib for the Treatment of Metastatic EGFR T790M Mutation–Positive Non–Small Cell Lung Cancer
2016
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Luning Zhuang | 276 | 234 | 142 | 177 | 24 | 628 | |
| April Barbour | 254 | 149 | 99 | 124 | 30 | 675 | |
| Anthony Jarkowski | 141 | 248 | 174 | 126 | 28 | 688 | |
| Susan Raber | 278 | 96 | 166 | 67 | 33 | 611 | |
| R Maller | 302 | 191 | 173 | 90 | 28 | 628 | |
| John Speth | 288 | 292 | 238 | 99 | 13 | 655 | |
| Gino Tripodi | 248 | 79 | 99 | 76 | 47 | 671 | |
| Byung Kee Kim | 133 | 65 | 51 | 166 | 28 | 587 | |
| Y. Valcke | 197 | 108 | 194 | 45 | 20 | 533 | |
| M. F. Kergueris | 200 | 62 | 135 | 70 | 31 | 518 | |
| Valerie Berry | 160 | 126 | 151 | 150 | 20 | 699 |
All Works
Login with ORCID to disown or claim papers
Loading papers...